Holen Sie sich die Stockscreener-App
1.55
92.43%
0.7445
Vorhandelsmarkt:
1.32
-0.23
-14.84%
Heartbeam Inc Aktie (BEAT) Neueste Nachrichten
Oracle, Synopsys, Heartbeam, Planet Labs And Adobe: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Heartbeam Inc. (BEAT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Heartbeam wins appeal, gains FDA clearance - BioWorld MedTech
FDA Greenlight Sends HeartBeam, Photronics, And Designer Brands Shares Climbing - Finimize
HeartBeam (BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal - Yahoo Finance
HeartBeam’s Leap: Should Investors Be Wary? - StocksToTrade
HeartBeam (BEAT) Stock: Surges 50% After FDA Grants Clearance For its 12-lead ECG Device - parameter.io
HeartBeam announces FDA clearance for 12-lead ECG synthesis software - TipRanks
HeartBeam price target raised to $5.50 from $2.50 at H.C. Wainwright - TipRanks
FDA clears HeartBeam’s at-home arrhythmia assessment tool - Yahoo
Weekly Trades: Is HeartBeam Inc stock recession proofTrade Entry Report & Community Trade Idea Sharing Platform - BỘ NỘI VỤ
Why Is Micro Cap HeartBeam Stock Surging On Wednesday? - Benzinga
HeartBeam Receives FDA Clearance for 12-Lead ECG for At-Home Arrhythmia Assessment - marketscreener.com
HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal - TradingView
HeartBeam Wins FDA Nod for Cable-Free 12-Lead ECG for Home Arrhythmia Assessment - Medical Product Outsourcing
HeartBeam shares skyrocket after FDA signs off on 12-lead ECG synthesis software - MSN
HeartBeam : Earnings Documents - marketscreener.com
HeartBeam stock soars after FDA clearance for 12-lead ECG synthesis software - Investing.com Nigeria
Why Is HeartBeam Stock (BEAT) Up Today? - TipRanks
Heartbeam rises after FDA clears its cable‑free ECG software - TradingView
HeartBeam’s 12-lead ECG synthesis software receives FDA clearance By Investing.com - Investing.com Australia
HeartBeam’s 12-lead ECG synthesis software receives FDA clearance - Investing.com India
HeartBeam earns FDA clearance for first-ever cable-free 12-lead ECG for at-home arrhythmia assessment - MassDevice
Why Did BEAT Stock Rocket 72% In Pre-Market Today? - Stocktwits
HC Wainwright & Co. Initiates Coverage of HeartBeam (BEAT) with Buy Recommendation - Nasdaq
An analyst sees good growth prospects for HeartBeam Inc (BEAT) - Setenews
HeartBeam (BEAT) Receives 'Buy' Rating from HC Wainwright & Co. - GuruFocus
HC Wainwright Initiates HeartBeam at Buy With $2.50 Price Target - marketscreener.com
HeartBeam initiated with a Buy at H.C. Wainwright - TipRanks
Will HeartBeam Inc stock deliver shareholder valueWeekly Investment Report & Stepwise Entry/Exit Trade Alerts - BỘ NỘI VỤ
How institutional buying supports HeartBeam Inc. stockEarnings Risk Summary & Daily Technical Forecast Reports - Newser
Why hedge funds are buying HeartBeam Inc. stockEarnings Miss & Technical Entry and Exit Alerts - Newser
Will HeartBeam Inc. stock maintain dividend yieldMarket Rally & Fast Exit Strategy with Risk Control - Newser
What is the fair value of HeartBeam Inc. Equity Warrant stock nowQuarterly Trade Summary & Advanced Swing Trade Entry Alerts - Newser
HeartBeam Pursues Regulatory Path After FDA Decision on ECG Software - citybuzz
HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software - Digital Journal
HeartBeam (BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software - NewMediaWire
HeartBeam Outlines Regulatory Strategy Following FDA Decision on ECG Software - citybuzz
HeartBeam Inc (BEAT) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Will HeartBeam Inc. Equity Warrant stock outperform tech sector in 2025Breakout Watch & Fast Gain Swing Alerts - moha.gov.vn
Biotech Minors Make Major Moves On FDA News And Stock Sales - Finimize
HeartBeam’s Strategic Path to Overcome Regulatory Challenges and Secure Buy Rating - TipRanks
Crude Oil Gains 1%; Tilray Brands Shares Plunge - Benzinga
Nasdaq Rises 100 Points; Chagee Shares Gain After Q3 Results - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
HeartBeam Outlines Regulatory Path Following FDA NSE Decision On 12-Lead ECG Synthesis Software - Nasdaq
Is HeartBeam Inc. stock dividend yield sustainableGold Moves & Safe Capital Growth Plans - BỘ NỘI VỤ
What's Behind HeartBeam's Over 40% After-Hours Surge? - Benzinga
HeartBeam, Inc. (BEAT) Stock: Soars as FDA Appeal Strategy Sparks Investor Optimism - parameter.io
HeartBeam pursues multiple options after FDA rejection of ECG software By Investing.com - Investing.com Nigeria
Heartbeam provides update on regulatory path following FDA decision on 12-lead ECG synthesis software application - marketscreener.com
Heartbeam Provides Update On Regulatory Path Following FDA Decision On 12-Lead ECG Synthesis Software Application - TradingView
HeartBeam pursues multiple options after FDA rejection of ECG software - Investing.com
HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application - The AI Journal
HeartBeam stock surges after FDA signals path forward on ECG software - Investing.com Nigeria
HeartBeam updates regulatory strategy for 12-lead ECG Synthesis Software - TipRanks
HeartBeam stock surges after FDA signals path forward on ECG software By Investing.com - Investing.com South Africa
1.74%
4.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):